Seeking Alpha: Can Teva Win With The Big Pharma Playbook?

There's no question that Teva Pharmaceuticals (TEVA) rewarded long-term investors with years and years of growth as it became the world's largest generic drug manufacturer. The biopharma world has changed, though, and so has Teva. Now branded companies like Novartis (NVS) and Sanofi (SNY) are in generics, and generic companies like Teva are in branded drugs. And just for good measure, a few outliers like Endo Pharmaceuticals (ENDP) add devices to the mix, while others like Abbott (ABT) and Covidien (COV) look to split and spin-off their drug businesses.

What's the point? Well, mostly that Teva probably has to start thinking more and more like Big Pharma if they want to continue to grow the business. It's hard to imagine that there's much buying left to do in the generic space (apart, perhaps, from a few select deals in specific markets), but there's plenty that the company could do in terms of buying branded drug/biotech businesses, or in-licensing compounds. Given the expense control management is showing, the synergy potentials alone could make M&A a viable path to growth.

Please read more here:
Can Teva Win With The Big Pharma Playbook?